A Phase 1 Clinical Trial of CA-4948 in Combination with Gemcitabine and NabPaclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Unresectable Pancreatic Ductal Carcinoma
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Adenocarcinoma of the pancreas has spread to other parts of the body and cannot be surgically removed
    2. Patients must have had disease progression on or after 5-FU-based therapy for metastatic or unresectable PDAC
    3. Patients on a cholesterol lowering statin must be on a stable dose with no dose changes within 3 weeks prior to study start

You may not be eligible for this study if the following are true:

    1. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study
    2. Patients who have not recovered from clinically significant adverse events due to prior anti-cancer therapy
    3. History of allogeneic organ or stem cell transplant



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.